课题基金 / 基金详情

BUDESONIDE CONTROLLED RELEASE CAPSULES AS MAINTENANCE IN CROHN'S DISEASE

BUDESONIDE CONTROLLED RELEASE CAPSULES AS MAINTENANCE IN CROHN'S DISEASE
布地奈德控释胶囊用于克罗恩病的维持治疗
批准号：
6281699
负责人：
ALAN L. BUCHMAN
金额：
$1.36万
依托单位：
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6281699
关键词：
Crohn's disease clinical research dosage forms gastrointestinal agents gastrointestinal disorder chemotherapy glucocorticoids human subject human therapy evaluation remission /regression

项目摘要

项目成果

ALAN L. BUCHMAN的其他基金

相似基金

相关文献

中文摘要
翻译
这项研究是为参与先前研究的患者设计的 布地奈德在活动性克罗恩病中的作用。它将决定是否 实现急性疾病缓解的患者将实现 服用布地奈德的缓解时间比服用安慰剂的时间更长。 在急性试验完成后，受试者将立即接受 随机接受布地奈德胶囊每天6毫克或安慰剂治疗 疗程52周。
英文摘要
This study is designed for patients who participated in a previous study of the drug budesonide in active Crohn's disease. It will determine if patients who have achieved remission of their acute disease will achieve a longer remission when taking budesonide than when taking placebo. Immediately upon completion of the acute trial, subjects will be randomized to receive budesonide capsules 6 mg daily or placebo for a treatment period of 52 weeks.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TREATMENT OF HEPATIC STEATOSIS ASSOCIATED WITH TOTAL PARENTAL NUTRITION
USE OF CLONIDINE TO REDUCE DIARRHEA LOSSES IN PATIENTS WITH PROXIMAL JEJUNOSTOMY
USE OF CLONIDINE TO REDUCE DIARRHEA LOSSES IN PATIENTS WITH PROXIMAL JEJUNOSTOMY
SAFETY AND EFFICACY OF ISIS 2302 IN STEROID DEPENDENT CROHN'S DISEASE
海外基金